Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

SYREN Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin) in Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1.

This study has been completed.
Information provided by (Responsible Party):
Hoffmann-La Roche Identifier:
First received: December 15, 2006
Last updated: April 2, 2016
Last verified: April 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: September 2010
  Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):